Meprobamate is a white powder with a characteristic odor and a bitter taste. It is slightly soluble in water, freely soluble in acetone and alcohol, and sparingly soluble in ether.
Meprobamate tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic.
The effectiveness of meprobamate tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.
Media Articles Related to Meprobamate
Depression and anxiety may be the first manifestations of a medical disease
Source: Anxiety / Stress News From Medical News Today [2015.02.13]
In the current issue of Psychotherapy and Psychosomatics, Fiammetta Cosci and other italian investigators have analyzed the data available on depression and anxiety as early manifestations of...
Instructional DVD reduces MRI scan patients' anxiety and improves scan quality
Source: MRI / PET / Ultrasound News From Medical News Today [2015.02.13]
A DVD designed to help people prepare for a Magnetic Resonance Imaging (MRI) scan, including guidance on how to relax, led to more successful scans.
Anxiety May Speed Aging
Source: MedicineNet Stress Specialty [2015.02.11]
Title: Anxiety May Speed Aging
Category: Health News
Created: 2/11/2015 12:00:00 AM
Last Editorial Review: 2/11/2015 12:00:00 AM
First glimpse of anxiety-related protein may lead to new drugs
Source: Bipolar News From Medical News Today [2015.02.02]
Previously dismissed as an unimportant protein, the first details of TSPO's molecular structure suggest its potential as a target for future anti-anxiety drugs.
Source: MedicineNet Bipolar Disorder Specialty [2015.01.07]
Category: Symptoms and Signs
Created: 10/13/2003 12:00:00 AM
Last Editorial Review: 1/7/2015 12:00:00 AM
Published Studies Related to Meprobamate
Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. [2003.06]
Implementation of regulations to control the prescribing of benzodiazepines in New York State in 1989 resulted in a 55% decrease in benzodiazepine prescribing, with a concomitant increase in the rates of prescribing older sedative-hypnotic compounds such as butabarbital (30% increase) and meprobamate (125% increase).
Reports of Suspected Meprobamate Side Effects
Toxicity TO Various Agents (28),
Respiratory Arrest (15),
Cardiac Arrest (15),
Accidental Death (14),
Drug Abuse (11),
Completed Suicide (11),
Multiple Drug Overdose Accidental (5),
Pulmonary Congestion (5),
Pulmonary Oedema (4), more >>
Page last updated: 2015-02-13